UNSPSC 51263016: Urapidil fumarate

This classification denotes an adrenergic alpha-1 receptor antagonist and antihypertensive agent C20H29N5O3.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7565ZXN22A, chemically known as 6-((3-(4-(2-methoxyphenyl)piperazin-1-yl)propyl)amino)-1,3-dimethylpyrimidine-2,4(1h,3h)-dione (2e)-but-2-enedioate (1:1), but more generally known as urapidil fumarate, which bears US NIH Compound Identifier 9870716. Most nations, for tariff and trade purposes, schedule urapidil fumarate under HS 29335995 and SITC 51576.

As of Q4 2014, URAPIDIL FUMARATE remains US FDA's Preferred Term for this commodity. SMILES: CN1C(CC(=O)N(C1=O)C)NCCCN2CCN(CC2)C3CCCCC3OC.C(=C/C(=O)O)\C(=O)O.

UNSPSC 51263016 Urapidil fumarate is a Commodity code that nominally identifies a specific antihypertensive pharmaceutical, but recent state and local procurement activity under this code does not align with that designation. The most recent opportunities tagged to this code involve procurement of naloxone (an opioid antagonist) and safe drug deactivation systems, and a request for information regarding direct-to-manufacturer prescription programs — neither of which relates to urapidil fumarate. State and local health agencies and purchasing offices appear to be using this code as a catch-all for pharmaceutical and pharmacy-benefit procurement rather than as a narrow product identifier, suggesting either misclassification at posting or a broader interpretation of the code's scope in practice.

Seminole County, Florida issued an IFB in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries, with a response deadline of July 26, 2023 and contract terms of two years plus a one-year renewal option; the procurement requires E-Verify compliance, workers' compensation and commercial general liability insurance, and potential FEMA funding with associated federal compliance obligations. The Texas Health and Human Services Commission concurrently issued an RFI in April 2026 to gather vendor capabilities for implementing a direct-to-manufacturer prescription program outside traditional pharmacy benefit manager and group purchasing organization channels, signaling early-stage market research before formal procurement. Geographic activity centers on Texas and Florida, with no clear pattern of repeat issuing bodies or geographic concentration evident from recent posts. Given the mismatch between the code's nominal scope and actual solicitation content, pursuit should be conditioned on confirmation that the opportunity genuinely matches your firm's pharmaceutical or pharmacy-program service lines rather than relying on the UNSPSC code designation.